All In Biotech

Drug Trial Radar · NCT07604766

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Jun 26, 2026

Primary completion

Sep 2027

Study completion Dec 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo. This study is an extension study of the protocol GCT1184-02 (NCT06619236).

Conditions

  • Platinum-resistant Ovarian Cancer

Interventions

  • Rina-SDrug

    Intravenous (IV) infusion

  • PaclitaxelDrug

    IV infusion

  • TopotecanDrug

    IV infusion

  • Pegylated liposomal doxorubicin (PLD)Drug

    IV infusion

  • GemcitabineDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 16 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • West China Second University Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Chongqing University Cancer Hospital - Chongqing Cancer Hospital

    Chongqing, China · Recruiting

  • Sun Yat-Sen Memorial Hospital

    Guangzhou, China · Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Shandong First Medical University Affiliated Tumor Hospital

    Jinan, China · Recruiting

  • Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)

    Nanjing, China · Recruiting

  • Fudan University Shanghai Cancer Hospital

    Shanghai, China · Recruiting

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.